PA
Perceptive Advisors Portfolio holdings
AUM
$2.67B
This Quarter Return
+17.73%
1 Year Return
+73.17%
3 Year Return
+837.18%
5 Year Return
+928.4%
10 Year Return
+11,818.45%
AUM
$3.02B
AUM Growth
+$3.02B
(+15%)
Cap. Flow
+$236M
Cap. Flow
% of AUM
7.81%
Top 10 Holdings %
Top 10 Hldgs %
52.68%
Holding
169
New
33
Increased
35
Reduced
22
Closed
35
Top Buys
| 1 |
BPMC
Blueprint Medicines
BPMC
|
$54M |
| 2 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$39.6M |
| 3 |
Merit Medical Systems
MMSI
|
$33.4M |
| 4 |
ABMD
Abiomed Inc
ABMD
|
$30.6M |
| 5 |
Neurocrine Biosciences
NBIX
|
$27.9M |
Top Sells
| 1 |
Alnylam Pharmaceuticals
ALNY
|
$58.2M |
| 2 |
NXTM
NxStage Medical Inc.
NXTM
|
$34.9M |
| 3 |
AnaptysBio
ANAB
|
$22.8M |
| 4 |
Puma Biotechnology
PBYI
|
$21.7M |
| 5 |
TSRO
TESARO, Inc.
TSRO
|
$21.5M |
Sector Composition
| 1 | Healthcare | 97.13% |
| 2 | Consumer Discretionary | 0.06% |
| 3 | Technology | 0.05% |
| 4 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Neurocrine Biosciences
NBIX
$13.8B
| $400M | 13.25% | 5,151,589 +360,000 | +8% | +$27.9M |
|
2
Amicus Therapeutics
FOLD
$2.34B
| $257M | 8.53% | 17,888,597 | – | – |
|
|
GBT
3
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $192M | 6.38% | 4,889,066 +625,000 | +15% | +$24.6M |
|
|
4
Alnylam Pharmaceuticals
ALNY
$58.5B
| $169M | 5.6% | 1,330,802 -458,000 | -26% | -$58.2M |
|
|
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
| $161M | 5.33% | 3,970,357 +300,000 | +8% | +$12.1M |
|
|
LJPC
6
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $109M | 3.61% | 3,388,611 +1,231,600 | +57% | +$39.6M |
|
|
BPMC
7
DELISTED
Blueprint Medicines
BPMC
| $86M | 2.85% | 1,140,434 +715,773 | +169% | +$54M |
|
|
8
AnaptysBio
ANAB
$569M
| $76.2M | 2.53% | 756,387 -225,882 | -23% | -$22.8M |
|
|
9
Puma Biotechnology
PBYI
$254M
| $69.6M | 2.31% | 703,820 -220,000 | -24% | -$21.7M |
|
|
XLRN
10
DELISTED
Acceleron Pharma Inc.
XLRN
| $68.6M | 2.27% | 1,616,259 | – | – |
|
11
Travere Therapeutics
TVTX
$1.56B
| $56.3M | 1.87% | 2,672,525 -13,679 | -0.5% | -$288K |
|
|
CORI
12
DELISTED
Corium International, Inc.
CORI
| $56.2M | 1.86% | 5,847,133 | – | – |
|
|
AVXS
13
DELISTED
AveXis, Inc. Common Stock
AVXS
| $53.1M | 1.76% | 480,141 -191,040 | -28% | -$21.1M |
|
14
CytomX Therapeutics
CTMX
$336M
| $52.6M | 1.74% | 2,490,381 +1,100,000 | +79% | +$23.2M |
|
|
DOVA
15
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
| $52.1M | 1.73% | 1,809,015 +55,000 | +3% | +$1.58M |
|
16
Regenxbio
RGNX
$451M
| $47.3M | 1.57% | 1,421,186 -20,000 | -1% | -$665K |
|
|
VBIV
17
DELISTED
VBI Vaccines, Inc. New Common Stock (Canada)
VBIV
| $41.3M | 1.37% | 9,665,843 +3,100,000 | +47% | +$13.2M |
|
|
ABMD
18
DELISTED
Abiomed Inc
ABMD
| $40.3M | 1.34% | 215,000 +163,271 | +316% | +$30.6M |
|
19
Iovance Biotherapeutics
IOVA
$807M
| $38.2M | 1.27% | 4,776,114 +50,000 | +1% | +$400K |
|
|
20
Merit Medical Systems
MMSI
$5.36B
| $37.8M | 1.25% | 874,013 +774,013 | +774% | +$33.4M |
|
21
argenx
ARGX
$43.6B
| $33.9M | 1.12% | 537,361 +87,361 | +19% | +$5.52M |
|
|
ALBO
22
DELISTED
Albireo Pharma, Inc. Common Stock
ALBO
| $33.8M | 1.12% | 1,320,000 +475,000 | +56% | +$12.2M |
|
23
Teleflex
TFX
$5.59B
| $31.3M | 1.04% | 125,900 +70,700 | +128% | +$17.6M |
|
|
MYOK
24
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $29.9M | 0.99% | 710,726 +160,009 | +29% | +$6.74M |
|
|
QTNT
25
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $29.7M | 0.98% | 6,033,020 +2,306,034 | +62% | +$11.3M |
|